MCID: DYS009
MIFTS: 41

Dysthymic Disorder

Categories: Mental diseases

Aliases & Classifications for Dysthymic Disorder

MalaCards integrated aliases for Dysthymic Disorder:

Name: Dysthymic Disorder 12 44 15 73
Dysthymia 12 76 55

Classifications:



External Ids:

Disease Ontology 12 DOID:12139
ICD10 33 F34.1
ICD9CM 35 300.4
MeSH 44 D019263
NCIt 50 C34562
SNOMED-CT 68 192384008 78667006
UMLS 73 C0013415

Summaries for Dysthymic Disorder

Disease Ontology : 12 A mood disorder that involves the presence of a low mood almost daily over a span of at least two years.

MalaCards based summary : Dysthymic Disorder, also known as dysthymia, is related to depression and personality disorder. An important gene associated with Dysthymic Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include colon, brain and testes, and related phenotype is muscle.

Wikipedia : 76 Dysthymia, now known as persistent depressive disorder (PDD), is a mood disorder consisting of the same... more...

Related Diseases for Dysthymic Disorder

Diseases related to Dysthymic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 depression 31.0 HTR2A MAOA SLC6A4
2 personality disorder 30.4 HTR2A MAOA SLC6A4
3 anxiety 30.4 HTR2A MAOA SLC6A4
4 atypical depressive disorder 30.4 GATA3 HTR7 MAOA SLC6A4
5 generalized anxiety disorder 30.2 HTR2A MAOA SLC6A4
6 obsessive-compulsive disorder 30.0 HTR2A MAOA SLC6A4
7 attention deficit-hyperactivity disorder 30.0 HTR2A MAOA SLC6A4
8 major depressive disorder 30.0 GATA3 HTR2A MAOA SLC6A4
9 borderline personality disorder 29.9 HTR2A MAOA SLC6A4
10 panic disorder 29.8 HTR2A MAOA SLC6A4
11 alcohol dependence 28.7 HTR2A HTR7 MAOA SLC6A4
12 alzheimer disease 5 10.4 HTR2A SLC6A4
13 schizoid personality disorder 10.4 HTR2A PIR
14 alcoholic psychosis 10.4 HTR2A SLC6A4
15 periodic limb movement disorder 10.4 HTR2A SLC6A4
16 social phobia 10.4 MAOA SLC6A4
17 bruxism 10.3 HTR2A SLC6A4
18 oppositional defiant disorder 10.3 MAOA SLC6A4
19 fibromyalgia 10.3 HTR2A SLC6A4
20 coronary artery vasospasm 10.3 HTR2A HTR7
21 antisocial personality disorder 10.2 MAOA SLC6A4
22 drug-induced mental disorder 10.2 HTR2A HTR7
23 drug psychosis 10.2 HTR2A HTR7
24 postpartum depression 10.2 MAOA SLC6A4
25 aging 10.2
26 bipolar i disorder 10.2 HTR2A SLC6A4
27 obsessive-compulsive personality disorder 10.2 PIR SLC6A4
28 conduct disorder 10.1 MAOA SLC6A4
29 pathological gambling 10.1 HTR2A MAOA SLC6A4
30 paranoid schizophrenia 10.1 HTR2A MAOA SLC6A4
31 early-onset schizophrenia 10.1 HTR2A MAOA SLC6A4
32 serotonin syndrome 10.1 HTR2A MAOA SLC6A4
33 bulimia nervosa 10.1 HTR2A MAOA SLC6A4
34 post-traumatic stress disorder 10.1 HTR2A MAOA SLC6A4
35 mood disorder 10.0 HTR2A MAOA SLC6A4
36 substance abuse 10.0 MAOA SLC6A4
37 chronic pulmonary heart disease 10.0 HTR7 SLC6A4
38 sudden infant death syndrome 10.0 HTR2A MAOA SLC6A4
39 intermittent explosive disorder 9.9 HTR7 SLC6A4
40 separation anxiety disorder 9.9 HTR7 PIR
41 phobic disorder 9.9 MAOA PIR SLC6A4
42 agoraphobia 9.8 MAOA PIR SLC6A4
43 schizoaffective disorder 9.8 HTR2A SLC6A4
44 alacrima, achalasia, and mental retardation syndrome 9.8
45 psychosexual disorder 9.8 HTR2A HTR7 SLC6A4
46 brunner syndrome 9.7 HTR7 MAOA SLC6A4
47 irritable bowel syndrome 9.7 HTR7 SLC6A4
48 parkinson disease, late-onset 9.6 HTR2A MAOA SLC6A4
49 chronic fatigue syndrome 9.6 MAOA SLC6A4
50 disease of mental health 9.4 HTR2A HTR7 MAOA SLC6A4

Comorbidity relations with Dysthymic Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Cystitis
Adjustment Disorder Anxiety
Atrophic Gastritis Atypical Depressive Disorder
Avoidant Personality Disorder Benign Essential Hypertension
Borderline Personality Disorder Bronchitis
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Esophagitis
Familial Atrial Fibrillation Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Irritable Bowel Syndrome Ischemic Heart Disease
Major Depressive Disorder Mitral Valve Disease
Mood Disorder Narcissistic Personality Disorder
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Opioid Addiction Oral Candidiasis
Osteoarthritis Osteoporosis
Paralytic Ileus Parkinson Disease, Late-Onset
Peripheral Vascular Disease Personality Disorder
Post-Traumatic Stress Disorder Postinflammatory Pulmonary Fibrosis
Postural Orthostatic Tachycardia Syndrome Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Dysthymic Disorder:



Diseases related to Dysthymic Disorder

Symptoms & Phenotypes for Dysthymic Disorder

MGI Mouse Phenotypes related to Dysthymic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.02 ELP1 GATA3 HTR2A MFSD8 SLC6A4

Drugs & Therapeutics for Dysthymic Disorder

Drugs for Dysthymic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4 58-22-0 6013
3
Testosterone enanthate Approved Phase 4 315-37-7 9416
4
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
5
Citalopram Approved Phase 4,Phase 2,Phase 3 59729-33-8 2771
6
Sertraline Approved Phase 4,Phase 2,Phase 3 79617-96-2 68617
7
Dopamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-61-6, 62-31-7 681
8
Fluoxetine Approved, Vet_approved Phase 4,Phase 2,Phase 3 54910-89-3 3386
9
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-41-2 439260
10
Bupropion Approved Phase 4,Phase 2,Phase 3 34841-39-9, 34911-55-2 444
11
Armodafinil Approved, Investigational Phase 4 112111-43-0
12
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
13
Imipramine Approved Phase 4 50-49-7 3696
14
Paroxetine Approved, Investigational Phase 4,Phase 2 61869-08-7 43815
15
Donepezil Approved Phase 4 120014-06-4 3152
16
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
17
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
18
Peppermint oil Approved, Investigational Phase 4 8006-90-4
19
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
20
Peppermint Approved, Nutraceutical Phase 4
21 Anabolic Agents Phase 4
22 Androgens Phase 4
23 Antineoplastic Agents, Hormonal Phase 4
24 Hormone Antagonists Phase 4
25 Hormones Phase 4
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
27 Testosterone 17 beta-cypionate Phase 4
28 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3
30 Antiparkinson Agents Phase 4,Phase 2,Not Applicable
31 Autonomic Agents Phase 4,Phase 2,Phase 1
32 Cholinergic Agents Phase 4,Phase 2,Phase 1
33 Cholinergic Antagonists Phase 4,Phase 2
34 Muscarinic Antagonists Phase 4,Phase 2
35 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
37 Parasympatholytics Phase 4,Phase 2
38 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
39 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Serotonin Agents Phase 4,Phase 2,Phase 3
41 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 3
42 Analgesics Phase 4,Not Applicable
43 Dopamine Agents Phase 4,Phase 2,Phase 3,Not Applicable
44 Duloxetine Hydrochloride Phase 4,Not Applicable
45 Monoamine Oxidase Inhibitors Phase 4
46 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
47 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Phase 3
48 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
49 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3
50 Central Nervous System Stimulants Phase 4,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 94)
# Name Status NCT ID Phase Drugs
1 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
2 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
3 Duloxetine Treatment in Elderly With Dysthymia Completed NCT01852383 Phase 4 Duloxetine
4 Wellbutrin XL for Dysthymic Disorder Completed NCT00225251 Phase 4 bupropion XL
5 Escitalopram in the Treatment of Dysthymic Disorder, Double Blind Completed NCT00220701 Phase 4 Lexapro (escitalopram)
6 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4 armodafinil;placebo
7 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
8 Desvenlafaxine vs. Placebo Treatment of Chronic Depression Completed NCT01537068 Phase 4 Desvenlafaxine;Placebo
9 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
10 Treatment of Depression Following Multiple Brain Tests Completed NCT00296777 Phase 4 Escitalopram;Bupropion;Imipramine
11 Dichotic Listening as a Predictor of Medication Response in Depression Completed NCT00296725 Phase 4 Fluoxetine;Imipramine
12 Are Two Antidepressants a Good Initial Treatment for Depression? Completed NCT00296712 Phase 4 escitalopram + bupropion
13 Dichotic Listening as a Predictor of Medication Response in Depression Completed NCT00404755 Phase 4 escitalopram;bupropion;imipramine
14 Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
15 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
16 A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression Completed NCT00296699 Phase 4 Duloxetine
17 Combination Treatment Study for Memory Impairment and Depression Completed NCT01658228 Phase 4 Donepezil;Placebo;Citalopram;Venlafaxine
18 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
19 Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults Recruiting NCT01973283 Phase 4 Antidepressant Medication
20 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) Recruiting NCT03518034 Phase 4 Testosterone;Placebo
21 Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction Terminated NCT00398632 Phase 4 Duloxetine
22 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
23 A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults Withdrawn NCT01942187 Phase 4 Aripiprazole;Bupropion
24 A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior Completed NCT01447602 Phase 3
25 A Stepped Care Model of Adolescent Depression Treatment in Primary Care Completed NCT01443715 Phase 2, Phase 3
26 Treatment of Adolescent Suicide Attempters (TASA) Completed NCT00080158 Phase 2, Phase 3 fluoxetine;sertraline;citalopram;escitalopram;bupropion;mirtazapine;venlafaxine;lithium
27 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
28 Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder Completed NCT00707980 Phase 3 Vortioxetine
29 A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND} Active, not recruiting NCT02358343 Phase 3 Antidepressant Drug Therapy
30 Effects of Therapist Behavior on the Treatment of Depressed Adolescents Unknown status NCT00073359 Phase 1, Phase 2
31 A Study of Omega-3 as a Treatment for Major Depression Unknown status NCT00238758 Phase 2 Omega-3 Polyunsaturated Fatty Acids
32 The Efficacy of Parent Involvement in the Treatment of Adolescent Depression Completed NCT00883519 Phase 1, Phase 2
33 New Approaches to Cocaine Abuse Medications (A) - 6 Completed NCT00000271 Phase 2 Desipramine;Placebo
34 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
35 Computerized Information-Processing Bias Retraining in Depressed Adolescents Completed NCT01147913 Phase 2
36 A Safety, Efficacy and Tolerability Study of SEP-225289 Completed NCT00584974 Phase 2 SEP-225289;SEP-225289;Venlafaxine;placebo
37 Group Interpersonal Psychotherapy for Depressed Adolescents in School-based Clinics Completed NCT00270244 Phase 2
38 Group Therapy for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
39 Bringing What Works to Youth in Corrections: A Trauma Intervention Completed NCT01560728 Phase 1, Phase 2
40 A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes Completed NCT02053272 Phase 2 GWP42004;Placebo
41 Smoking Cessation for Depressed Smokers Active, not recruiting NCT00494728 Phase 1, Phase 2 Nicotine Replacement Therapy
42 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Enrolling by invitation NCT02458690 Phase 2 Antidepressant Medications
43 Interpersonal Psychotherapy for Depressed Adolescents and Parents Completed NCT00619411 Phase 1
44 Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression Completed NCT00356304 Phase 1
45 Evaluating a Novel Internet Intervention for Persons With Epilepsy and Depression Unknown status NCT02791724 Not Applicable
46 Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression Unknown status NCT01473615 Not Applicable
47 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Unknown status NCT02707848
48 Internet-delivered Transdiagnostic Intervention for Anxiety and Depression Unknown status NCT02739607 Not Applicable
49 Desvenlafaxine Monotherapy in Dysthymia Completed NCT01948895 Not Applicable Desvenlafaxine
50 Duloxetine for the Treatment of Dysthymia Completed NCT00185575 Not Applicable duloxetine

Search NIH Clinical Center for Dysthymic Disorder

Cochrane evidence based reviews: dysthymic disorder

Genetic Tests for Dysthymic Disorder

Anatomical Context for Dysthymic Disorder

MalaCards organs/tissues related to Dysthymic Disorder:

41
Colon, Brain, Testes, Spinal Cord

Publications for Dysthymic Disorder

Articles related to Dysthymic Disorder:

(show top 50) (show all 115)
# Title Authors Year
1
Changes in cytokine and chemokine expression distinguish dysthymic disorder from major depression and healthy controls. ( 27992767 )
2017
2
Cognitive Vulnerability in Patients with Generalized Anxiety Disorder, Dysthymic Disorder and Normal Individuals. ( 27045393 )
2016
3
Assessment of Quality of Life (QOL) in Obsessive Compulsive Disorder (OCD) and Dysthymic Disorder (DD): A Comparative Study. ( 26155540 )
2015
4
Frontoparietal function in young people with dysthymic disorder (DSM-5: Persistent depressive disorder) during spatial working memory. ( 24709020 )
2014
5
The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? ( 24270481 )
2014
6
Relationship of quality of life with disability grade in obsessive compulsive disorder and dysthymic disorder. ( 25191009 )
2014
7
An open treatment trial of duloxetine in elderly patients with dysthymic disorder. ( 25177490 )
2014
8
Add-on deep transcranial magnetic stimulation (dTMS) in patients with dysthymic disorder comorbid with alcohol use disorder: A comparison with standard treatment. ( 25140585 )
2014
9
Dysthymic disorder in the elderly population. ( 24152873 )
2014
10
L-acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. ( 23428336 )
2013
11
Controlled randomized clinical trial of spirituality integrated psychotherapy, cognitive-behavioral therapy and medication intervention on depressive symptoms and dysfunctional attitudes in patients with dysthymic disorder. ( 24516853 )
2013
12
An examination of generalized anxiety disorder and dysthymic disorder by latent class analysis. ( 24020863 )
2013
13
Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study. ( 23466114 )
2013
14
Efficacy of add-on deep transcranial magnetic stimulation in comorbid alcohol dependence and dysthymic disorder: three case reports. ( 23724355 )
2013
15
Are there temperament differences between major depression and dysthymic disorder in adolescent clinical outpatients? ( 21839431 )
2012
16
The categorisation of dysthymic disorder: can its constituents be meaningfully apportioned? ( 22835850 )
2012
17
Are there meaningful differences between major depressive disorder, dysthymic disorder, and their subthreshold variants? ( 22922240 )
2012
18
Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. ( 21536001 )
2011
19
Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. ( 21869696 )
2011
20
Trajectories of recovery of social and physical functioning in major depression, dysthymic disorder and double depression: a 3-year follow-up. ( 19945171 )
2010
21
The association of visuospatial working memory with dysthymic disorder in pre-pubertal children. ( 19607749 )
2010
22
The impact of comorbid dysthymic disorder on outcome in personality disorders. ( 20728000 )
2010
23
Escitalopram versus placebo in the treatment of dysthymic disorder. ( 21811192 )
2010
24
Four cases of dysthymic disorder and general malaise successfully treated with traditional herbal (kampo) medicines: kamiuntanto. ( 21614161 )
2010
25
Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age- and sex-matched major depressed patients and healthy controls. ( 21312291 )
2010
26
The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. ( 21190638 )
2010
27
Impairment in psychosocial functioning associated with dysthymic disorder in the NESARC study. ( 20471093 )
2010
28
The three-year naturalistic course of major depressive disorder, dysthymic disorder and double depression. ( 19042028 )
2009
29
Dysthymic disorder: forlorn and overlooked? ( 19724735 )
2009
30
Do major depressive disorder and dysthymic disorder confer differential risk for suicide? ( 18842304 )
2009
31
The effects of dysthymic disorder on health-related quality of life and disability days in persons with comorbid medical conditions in the general population. ( 19270471 )
2009
32
Comparison of prototypic cases of depressive personality disorder and dysthymic disorder. ( 18825775 )
2008
33
Dysthymic disorder and double depression: prediction of 10-year course trajectories and outcomes. ( 17466334 )
2008
34
Plasma testosterone and dehydroepiandrosterone sulfate in male and female patients with dysthymic disorder. ( 17182106 )
2007
35
Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. ( 16648329 )
2006
36
Comparison of psychosocial correlates in primary school age children with attention deficit/ hyperactivity disorder- combined type, with and without dysthymic disorder. ( 16755402 )
2006
37
Attention deficit hyperactivity disorder, combined type, dysthymic disorder and anxiety disorders: differential patterns of neurodevelopmental deficits. ( 16876876 )
2006
38
Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. ( 15653941 )
2005
39
Characteristics of internalizing and externalizing disorders in medication-naive, clinically referred children with attention deficit hyperactivity disorder, combined type and dysthymic disorder. ( 15860023 )
2005
40
Mental health service use by patients with dysthymic disorder: treatment use and dropout in a 7 1/2-year naturalistic follow-up study. ( 16175754 )
2005
41
Longitudinal comparison of depressive personality disorder and dysthymic disorder. ( 16175753 )
2005
42
Dysthymic disorder contributes to oppositional defiant behaviour in children with Attention Deficit Hyperactivity Disorder, combined type (ADHD-CT). ( 15935256 )
2005
43
An open treatment trial of venlafaxine for elderly patients with dysthymic disorder. ( 15533993 )
2004
44
Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. ( 15013252 )
2004
45
Psychopathology in the adolescent and young adult offspring of parents with dysthymic disorder and major depressive disorder. ( 15091300 )
2004
46
Trait and state aspects of harm avoidance and its implication for treatment in major depressive disorder, dysthymic disorder, and depressive personality disorder. ( 15149288 )
2004
47
Citalopram in the treatment of dysthymic disorder. ( 15107656 )
2004
48
A growth curve analysis of the course of dysthymic disorder: the effects of chronic stress and moderation by adverse parent-child relationships and family history. ( 15612848 )
2004
49
Phenomenology and comorbidity of dysthymic disorder in 100 consecutively referred children and adolescents: beyond DSM-IV. ( 12655907 )
2003
50
Current therapeutic approaches for dysthymic disorder. ( 19810854 )
2003

Variations for Dysthymic Disorder

Expression for Dysthymic Disorder

Search GEO for disease gene expression data for Dysthymic Disorder.

Pathways for Dysthymic Disorder

GO Terms for Dysthymic Disorder

Biological processes related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.43 GATA3 HTR2A SLC6A4
2 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.32 HTR2A HTR7
3 phosphatidylinositol 3-kinase signaling GO:0014065 9.16 GATA3 HTR2A
4 smooth muscle contraction GO:0006939 8.96 HTR2A HTR7
5 vasoconstriction GO:0042310 8.62 HTR7 SLC6A4

Molecular functions related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.16 HTR2A HTR7
2 G-protein coupled serotonin receptor activity GO:0004993 8.96 HTR2A HTR7
3 serotonin binding GO:0051378 8.62 HTR2A HTR7

Sources for Dysthymic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....